B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIN1

MOLECULAR TARGET

glutamate ionotropic receptor NMDA type subunit 1

UniProt: Q05586NCBI Gene: 290220 compounds

GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIN1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Glutamic Acid3.4029
2Glutamic Acid3.4029
3Glycine2.7715
4pentamidine1.956
5Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of1.795
6Dextrorphan Dextro form of levorphanol. It acts as1.795
7Levorphanol1.795
8cycloserine1.614
9Aspartic Acid1.393
10eliprodil1.393
11Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as1.393
12D-Aspartic Acid1.102
13Ethidium1.102
14Kynurenic Acid1.102
15Phenformin0.691
16Carvedilol0.691
17Dextrothyroxine0.691
18Dizocilpine Maleate0.691
19Ibotenic Acid0.691
20Spermine0.691

About GRIN1 as a Drug Target

GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented GRIN1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIN1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.